Tirzepatide improves outcomes in patients with obesity-related HFpEF regardless of the severity of their baseline BMI or fat ...

Tirzepatide outperformed semaglutide in simultaneously achieving four key therapeutic targets for type 2 diabetes.

Hormone therapy as an adjunctive to tirzepatide was associated with greater weight loss than tirzepatide alone among postmenopausal women.

Key TakeawaysThe weight-loss drug tirzepatide reduced both body fat and tumor growth in obese mice with breast cancer. Tumor ...

In a striking new study, the anti-obesity drug tirzepatide, known as Mounjaro and Zepbound, not only triggered significant ...

Patients prescribed drugs to help them lose weight may experience a rebound in weight gain after halting their prescription, ...

Researchers found that tirzepatide, a medication primarily used for treating type 2 diabetes and weight loss, reduced body ...

Glucagon-like peptide 1 receptor agonists may offer neuroprotective and survival benefits beyond blood sugar control.

Postmenopausal women struggling with weight loss may find a powerful solution by combining the diabetes drug tirzepatide with menopause hormone therapy. A Mayo Clinic study revealed that this dual ...

GLP-1 receptor agonist drugs like Ozempic help people manage type 2 diabetes. Foods like Greek yogurt and avocados can't do ...

More data, this time from a large observational study, are bolstering the idea that glucagon-like peptide-1 (GLP-1) receptor ...

GLP-1 drugs like semaglutide (Ozempic) and tirzepatide (Mounjaro) may shrink fat, but also crucial muscle mass, with little evidence of improving cardiorespiratory fitness, researchers say.